Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q3 2019 · 10-Q
Revenue$14.70M$14.70M+177.0% vs Q3 2018 Net Income-$34.58M-$34.58MN/M vs Q3 2018 EPS Diluted-$0.94-$0.94N/M vs Q3 2018 Operating Income-$35,896,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$31,832,000N/M Margins · derivedOperating margin-244.2%+184.1 pt vs Q3 2018
Net margin-235.3%+126.6 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 5, 2019 · 36 d after period end